The participating health insurance companies pursue the goal of concluding discount agreements for the active substance abatacept with all suitable pharmaceutical companies in accordance with section 130a (8) of the German Civil Code (SGB V). The contract is concluded as part of the open house biology process of the health insurance companies:

Individual negotiations on contract content are not conducted, uniform conditions apply. The health insurance companies do not guarantee exclusivity to individual contractual partners. The contract period is a maximum of 24 months starting on December 1, 2021. The contract ends no later than 30.11.2023, regardless of the date of conclusion of the contract. All further information can be found in the participation and contract documents.

It is possible to join this open house biological process at any time within the contract period.

A contract is concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration for approval and for the company) and who confirm this in electronic form in accordance with § 126a BGB.

This publication does not concern the award of a public contract within the meaning of the Procurement Law Directive (2014/24/EC) or antitrust procurement law. In the interest of informing interested pharmaceutical entrepreneurs as broadly as possible, this notice will be made in the supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text according to section IV.1.1) and the indication of award criteria in accordance with item II.2.5) are due to the specifications of the publication form and have no further meaning. This and the use of the medium “TED” does not involve any submission to public procurement regulations whose validity is not mandatory by law or procurement regulations.